- Corporate
- Products
- For Print
- April 29, 2026
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the global revenue (pre-audit basis) of the anti-amyloid-beta protofibril antibody “LEQEMBI®” (generic name: lecanemab) was JPY 88.0 billion for the fiscal year 2025 (April 1, 2025 – March 31, 2026). By major markets, revenue came to JPY 44.6 billion in the United States, JPY 24.4 billion in Japan, and JPY 12.4 billion in China.
This information is being disclosed in conjunction with today’s announcement of the financial results for the first quarter of 2026 by Biogen Inc. (Headquarters: Cambridge, Massachusetts). Eisai’s financial results for the fiscal year 2025, including details of LEQEMBI’s revenue, will be disclosed in Eisai's financial disclosure scheduled for May 15, 2026.
Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen Inc. co-commercializing and co-promoting the product and Eisai having final decision-making authority.
Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
Our news releases are intended to disclose corporate information and are not intended for the promotion or advertising of prescription pharmaceuticals or investigational products, nor are they intended to provide medical advice.
Please note that the information contained in news releases is current as of the date of publication.